{"nctId":"NCT00393718","briefTitle":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2006-11"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":400,"armGroups":[{"label":"Liraglutide","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide","Drug: placebo"]},{"label":"Glibenclamide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: glibenclamide","Drug: placebo"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"glibenclamide","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight weeks\n* HbA1c greater than or equal to 7.0% and less than 10.0%\n* BMI (Body Mass Index) less than 35 kg/m2\n\nExclusion Criteria:\n\n* Treatment with insulin within the last 12 weeks\n* Treatment with any drug that could interfere with the glucose level\n* Any serious medical condition\n* Females who are pregnant, have intention of becoming pregnant or are breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.99","spread":"0.07"},{"groupId":"OG001","value":"7.50","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.31","spread":"0.08"},{"groupId":"OG001","value":"7.80","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose After 24 Weeks of Treatment","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137.2","spread":"1.9"},{"groupId":"OG001","value":"150.1","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose After 52 Weeks of Treatment","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.8","spread":"2.4"},{"groupId":"OG001","value":"157.5","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Postprandial Glucose AUC After 24 Weeks of Treatment","description":"Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"557.54","spread":"9.53"},{"groupId":"OG001","value":"670.60","spread":"12.69"}]}]}]},{"type":"SECONDARY","title":"Postprandial Glucose AUC After 52 Weeks of Treatment","description":"Postprandial glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"608.66","spread":"11.18"},{"groupId":"OG001","value":"683.17","spread":"14.96"}]}]}]},{"type":"SECONDARY","title":"Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment","description":"Plasma glucose (PG) profile measured after 24 weeks of treatment. The time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.98","spread":"2.61"},{"groupId":"OG001","value":"173.61","spread":"3.51"}]}]}]},{"type":"SECONDARY","title":"Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment","description":"Mean plasma glucose(PG) in 7-point plasma glucose profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167.39","spread":"3.22"},{"groupId":"OG001","value":"184.60","spread":"4.34"}]}]}]},{"type":"SECONDARY","title":"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment","description":"Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.69","spread":"2.83"},{"groupId":"OG001","value":"79.66","spread":"3.75"}]}]}]},{"type":"SECONDARY","title":"Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment","description":"Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.56","spread":"2.96"},{"groupId":"OG001","value":"76.59","spread":"3.94"}]}]}]},{"type":"SECONDARY","title":"Body Weight After 24 Weeks of Treatment","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.06","spread":"0.15"},{"groupId":"OG001","value":"65.97","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Body Weight After 52 Weeks of Treatment","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.30","spread":"0.19"},{"groupId":"OG001","value":"66.01","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Hypoglycaemic Episodes","description":"Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.694","spread":null},{"groupId":"OG001","value":"3.843","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.187","spread":null},{"groupId":"OG001","value":"1.103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.507","spread":null},{"groupId":"OG001","value":"2.740","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":268},"commonTop":["Nasopharyngitis","Diarrhoea","Upper respiratory tract inflammation","Constipation","Back pain"]}}}